Jazz targets US launch of SCLC drug after FDA grants fast review

Jazz targets US launch of SCLC drug after FDA grants fast review

Submitted by admin on February 17, 2020 - 10:21am
Source: 
Pharmaforum
News Tags: 
PharmaMar
Jazz Pharmaceuticals
FDA
small cell lung cancer
lurbinectedin
priority review
Headline: 
Jazz targets US launch of SCLC drug after FDA grants fast review
snippet: 

PharmaMar and Jazz Pharmaceuticals have announced the FDA has granted a six-month Priority Review for their lurbinectedin for relapsed small cell lung cancer (SCLC).

Do Not Allow Advertisers to Use My Personal information